

DAFTAR PUSTAKA

A. Malik, F. Kamal, R. Basharat, A. Naz MI. Correlation between Ki-67 index and Her-2 Expression Status in Invasive Ductal Carcinoma of Breast. Published online 2022.

Alqarny M. Overview of the different surgical modalities for correction of caudal septal dislocation; a review article. *Tech Biochem.* 2023;6:1-11. doi:10.47577/biochemmed.v6i.8697

An J, Peng C, Tang H, Liu X, Peng F. New advances in the research of resistance to neoadjuvant chemotherapy in breast cancer. *Int J Mol Sci.* 2021;22(17). doi:10.3390/ijms22179644

Ana Gabriela Colima Fausto, Sergio Yair Rodríguez Preciado, Annette Medina Valentín, Adrianna G. Caro Baella PAAR. The presence of PIK3CA gene mutations and possible implications in breast cancer. Published online 2023.

A. Malik, F. Kamal, R. Basharat, A. Naz MI. Correlation between Ki-67 index and Her-2 Expression Status in Invasive Ductal Carcinoma of Breast. Published online 2022.

Antonini M, Mattar A, Pannain GD, et al. Integrative review of clinical trials and meta analysis of the main studies of neoadjuvant chemotherapy in the treatment of breast cancer in the past 30 years. *Mastology.* 2023;33. doi:10.29289/2594539420230027

Arpino G, Ciocca DR, Weiss H, et al. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase II α for anthracycline chemotherapy in locally advanced breast cancer. *Breast Cancer Res Treat.* 2005;92(1):69-75. doi:10.1007/s10549-005-1721-9

Atik Diah Mutiara Ningsih, Rafif Shidqi SA. Management of Breast Cancer with Curcumae Rhizoma: A Therapeutic Approach. Published online 2023

Banys-paluchowski M, Gasparri ML, de Boniface J, et al. Surgical management of the axilla in clinically node-positive breast cancer patients converting to clinical

node negativity through neoadjuvant chemotherapy: Current status, knowledge gaps, and rationale for the eubrest-03 axsana study. *Cancers (Basel)*. 2021;13(7). doi:10.3390/cancers13071565

Beghein E, Van Audenhove I, Zwaenepoel O, Verhelle A, De Ganck A, Gettemans J. A new survivin tracer tracks, delocalizes and captures endogenous survivin at different subcellular locations and in distinct organelles. *Sci Rep*. 2016;6. doi:10.1038/srep31177

Bernard K, Kingsley A, Ikechukwu N. The Breast Cancer Steroid/HER-2 Receptor Profile Immunohistochemistry in Imo State: A Private Center Experience. *Int J Heal Sci Res*. 2023;13(1):11-18. doi:10.52403/ijhsr.20230103

Bhardwaj P V., Mason H, Kaufman SA, Visintainer P, Makari-Judson G. Outcomes of a Multidisciplinary Team in the Management of Patients with Early-Stage Breast Cancer Undergoing Neoadjuvant Chemotherapy at a Community Cancer Center. *Curr Oncol*. 2023;30(5):4861-4870. doi:10.3390/curroncol30050366

Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I. and Jemal, A. (2024) ‘Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries’, *CA: A Cancer Journal for Clinicians*, 74(3), pp. 229–263. Available at: <https://doi.org/10.3322/caac.21834>.

Carpenter RL, Lo HW. Regulation of Apoptosis by HER2 in Breast Cancer. *J Carcinog Mutagen*. 2013;S7: 003. Available from: <http://dx.doi.org/10.4172/2157-2518>. Accessed Februari 8 2015.

Chia S, Ung K, Bramwell V, et al. Prognostic and Predictive Impact of Intrinsic Biological Classification by Immunohistochemistry (IHC) and QPCR for Adjuvant Tamoxifen in Pre-Menopausal Breast Cancer: Results from the NCIC CTG MA.12 Trial. *Cancer Res*. 2009;69(24_Supplement):4056-4056. doi:10.1158/0008-5472.sabcs-09-4056

Cobain EF, Hayes DF. Expanding the reach of HER2-targeted therapies: transformation of an historical paradigm. *J Clin Invest*. 2022;132(24). doi:10.1172/JCI166384

Cosgrave N, Hill AD, Young LS. Growth Factor Dependent Regulation of Survivin by C-myc in Human Breast Cancer. *Journal of Molecular Endocrinology*. 2006; 37: 377-390.

D'Agata A. The role of neo-adjuvant chemotherapy in the treatment of breast cancer. *G Ital di Senol.* 1990;11(1-2):39-49.

Dario C. Altieri, survivin and iap proteins in cell death mechanisms by *Biochem J.* 2010 September 1; 430(2): 199–205. doi:10.1042/BJ20100814, 2011

Fabbri A, Nelli F, Botticelli A, et al. Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neoparl nationwide collaborative study. *Front Oncol.* 2023;13. doi:10.3389/fonc.2023.1177681

Fehm T, Ruckhäberle E. Breast cancer. *Metab Hum Dis Organ Physiol Pathophysiol.* Published online 2014:379-384. doi:10.1007/978-3-7091-0715-7_55

Fuzhong T, Nan L, Jiajia G, Miao L, Deqi Y. Clinical significance of the relationship between expression of survivin and effects of neoadjuvant chemotherapy in locally advanced breast cancer. *Gan To Kagaku Ryoho.* 2008;35(8):1319-1323.

Fountzilas, G., Dafni, U., Bobos, M., Kotoula, V., Batistatou, A., Xanthakis, I., Papadimitriou, C., Kostopoulos, I., Koletsa, T. & Tsolaki, E. 2013. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. *BMC cancer*, 13, 123-63.

Furrer D, Paquet C, Jacob S, Diorio C. The Human Epidermal Growth Factor Receptor 2 (HER2) as a Prognostic and Predictive Biomarker: Molecular Insights into HER2 Activation and Diagnostic Implications. *Cancer Progn.* Published online 2018. doi:10.5772/intechopen.78271

Garg H, Suri P, Gupta JC, Talwar GP, Dubey S. Survivin: A unique target for tumor therapy. *Cancer Cell Int.* 2016;16(1). doi:10.1186/s12935-016-0326-1

Glynn-Jones R, Grainger J, Harrison M, Ostler P, Makris A. Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: Should we be more cautious? *Br J Cancer.* 2006;94(3):363-371. doi:10.1038/sj.bjc.6602960

I. T, S. R, H.A. K, A. L, H.M. K, R.U. K. Correlation between neoadjuvant chemotherapy response and ER, PGR and Her-2 expression in breast cancer. *Pakistan J Med Heal Sci.* 2013;7(3):614-617.

Ibrahim SEAM, Hasan AM, Mohamed AAH, Bessar AA. Era of Mucormycosis in Covid-19 Pandemic; Overview, Radiological Imaging and Management: Review Article. *Egypt J Hosp Med.* 2023;91(1):5340-5344. doi:10.21608/ejhm.2023.305101

Hamy AS, Bieche I, Lehmann-Che J, et al. BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy. *Breast Cancer Res Treat.* 2016;159(3):499-511. doi:10.1007/s10549-016-3961-2

Han R, Wang G, Zhang Y, Zhao X. Efficacy of neoadjuvant chemotherapy combined with bevacizumab versus neoadjuvant chemotherapy alone for Her2-negative breast cancer: a meta-analysis of randomized controlled clinical trials. *Zhejiang Da Xue Xue Bao Yi Xue Ban.* 2016;45(4):379-386.

Kumkum Jha, Mridula Shukla, Manoj Pandey, Survivin expression and targeting in breast cancer by PubMed Surg Oncology. 2012 Jun;21(2):125-31. doi: 10.1016/j.suronc.2011.01.001

Luh Dewi, I Gusti A Artha, Herman Saputra, Hubungan Ekspresi Survivin dengan sub tipe molekuler berbasis imunohistokimia pada karsinoma payudara invasif tipe tidak spesifik, 2017

Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—An updated review. *Cancers (Basel).* 2021;13 (17). doi:10.3390/cancers13174287

L. Xiaoxu. Relationship between survivin expression in breast cancer and the efficacy of different neoadjuvant chemotherapy regimens. Published online 2008.

Mellissa J. Hicks, Erin R. Macrae, M. Abdel-Rasoul, R. Layman, S. Friedman, J. Querry, M. Lustberg, B. Ramaswamy, E. Mrózek CS. Breast Cancer Neoadjuvant Dual HER 2-Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER 2-

Positive Breast Cancer : A Meta-Analysis of Randomized Prospective Clinical Trials. Published online 2015.

Mollica V, Maggio I, Lopez-Beltran A, et al. Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. *Expert Rev Anticancer Ther.* 2020;20(9):755-763. doi:10.1080/14737140.2020.1807334

Nam KS, Son SH, Oh S, et al. Binding of galectin-1 to integrin β 1 potentiates drug resistance by promoting survivin expression in breast cancer cells. *Oncotarget.* 2017;8(22):35804-35823. doi:10.18632/oncotarget.16208

Nasib SMA, Alkhudaidy RMM. Overview on Prevalence, Etiology, and Management of Calcium Pyrophosphate Deposition (CPPD) Disease: Review article. *Egypt J Hosp Med.* 2023;91(1):5036-5044. doi:10.21608/ejhm.2023.303619

Payal B, Kirti R. Comparison of ER, PR and HER-2/NEU reactivity pattern with histological grade, type, tumour size, Lymphovascular invasion, mitotic index and lymph node status in breast cancer. *Int J Clin Diagnostic Pathol.* 2021;4(1):108-112. doi:10.33545/pathol.2021.v4.i1b.335

Peng Y, Binghe X. Progression of HER-2 lowly expressed breast cancer and the related anti-tumor drugs. *Chinese J Oncol.* 2021;43(9):901-905. doi:10.3760/cma.j.cn112152-20210220-00149

Rustamadji P, Wiyarta E, Anggreani I. Correlation of Before and After Invasive Breast Cancer Neoadjuvant Chemotherapy for NFkB, Cyclin D1, and Survivin Expression. *Iran J Pathol.* 2023;18(2):147-155. doi:10.30699/IJP.2023.562935.2983

Perez EA. HER-2 as a prognostic, predictive, and therapeutic target in breast cancer. *Cancer Control.* 1999;6(3):233-240. doi:10.1177/107327489900600301

Pluta P, Jesionek-Kupnicka D, Pluta A, et al. Prognostic value of XIAP and survivin expression in locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy. *Arch Med Sci.* 2023;19(2):343-354. doi:10.5114/aoms.2019.88509

Primariadewi Rustamadji, Elvan wiyarta, Ineke anggreini, Exploring the Expression of Survivin in Invasive Breast Carcinoma, 2022

Primariadewi Rustamadji, Elvan wiyarta, Ineke angg्रेini, Correlation of Before and After Invasive Breast Cancer Neoadjuvant Chemotherapy for NFkB, Cyclin D1, and Survivin Expression, 2023

Raharjo CA, Herviastuti R, Darwito, et al. Pathological profiles and clinical management challenges of breast cancer emerging in young women in Indonesia: a hospital-based study. *BMC Womens Health*. 2019;19(1):N.PAG-N.PAG.

Sandhu GS, Erqou S, Patterson H, Mathew A. Prevalence of Triple-Negative Breast Cancer in India: Systematic Review and Meta-Analysis. *J Glob Oncol*. 2016;2(6):412-421. doi:10.1200/jgo.2016.005397

S. Dent, B. Oyan, A. Honig, M. Mano SH. Anti-Tumour Treatment HER 2-targeted therapy in breast cancer : A systematic review of neoadjuvant trials. Published online 2013.

Silvana Di Palma, Panagiotis Koliou, Alex Simonovic, Daniela Costa, Catherine Faulkes, Brenda Kobutungi, Felicity Paterson, J. Horsnell, F. Pakzad, Tracey Irvine, P. Partlett, Elizabeth Clayton NC. Breast Cancer Molecular Subtyping in Practice: A Real-World Study of the APIS Breast Cancer Subtyping Assay in a Consecutive Series of Breast Core Biopsies. Published online 2024.

Simanjuntak MV, Jauhar MM, Syaifie PH, et al. Revealing Propolis Potential Activity on Inhibiting Estrogen Receptor and Heat Shock Protein 90 Overexpressed in Breast Cancer by Bioinformatics Approaches. *Bioinform Biol Insights*. 2024;18. doi:10.1177/11779322231224187

Skalova A, Vanecek T, Losan F, Papoutsidesova, Finek J. [Detection of HER-2/neu in breast carcinoma]. *Cas Lek Ces*. 2003;142(2):93-98.

Solikhah S, Matahari R, Utami FP, Handayani L, Marwati TA. Breast cancer stigma among Indonesian women: A case study of breast cancer patients. *BMC Womens Health*. 2020;20(1). doi:10.1186/s12905-020-00983-x

Sousa IM de, Marin Comini ACC, Borges IB e S, Tavares MC. Clinical and pathological description of patients with triple negative breast cancer undergoing neoadjuvant chemotherapy and pembrolizumab in a Brazilian cancer center. *J Clin Oncol*. 2023;41(16_suppl):e14632-e14632. doi:10.1200/jco.2023.41.16_suppl.e14632

Souza KCB, Evangelista AF, Leal LF, et al. Identification of Cell-Free Circulating MicroRNAs for the Detection of Early Breast Cancer and Molecular Subtyping. *J Oncol*. 2019;2019. doi:10.1155/2019/8393769

Spring LM, Fell G, Arfe A, et al. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. *Clin Cancer Res*. 2020;26(12):2838-2848. doi:10.1158/1078-0432.CCR-19-3492

Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2022) ‘Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries’, *CA: A Cancer Journal for Clinicians*, 71(3), pp. 209–249. Available at: <https://doi.org/10.3322/caac.21660>.

Swellam M, Arab LRE El, Bushnak HA. Clinical implications of HER-2/neu overexpression and proteolytic activity imbalance in breast cancer. *IUBMB Life*. 2007;59(6):394-401. doi:10.1080/15216540701395074

Tian H, Ma D, Tan X, et al. Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review. *Front Pharmacol*. 2021;12. doi:10.3389/fphar.2021.770663

Tong L, Yu X, Wang S, Chen L, Wu Y. Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer. *Breast Cancer Targets Ther*. 2023;15:647-658. doi:10.2147/BCTT.S426121

Wu L, Xu Y, Zhao H. HER 2 Targeted Therapy and Its Potential Risk of Drug Resistance. *Theor Nat Sci*. 2023;3(1):141-149. doi:10.54254/2753-8818/3/20220210

Xiaoxu L. Relationship between survivin expression in breast cancer and the efficacy of different neoadjuvant chemotherapy regimens. Published online 2008.

Xin L, Liu Q, Xu L, et al. Role of magnetic resonance imaging for response evaluation and predictive value of tumor biomarkers in the neoadjuvant chemotherapy for breast cancer: a multi-center prospective study. *Natl Med J China*. 2014;94(26):2018-2021. doi:10.3760/cma.j.issn.0376-2491.2014.26.005

Yi-Xin Zhao D kun Z. Efficacy and safety of trastuzumab combined with neoadjuvant chemotherapy in Chinese patients with HER-2 positive breast cancer: a meta-analysis. Published online 2022.

Yong-Gang L, Fang Yu, Qing Yao, Jiang-Hao Chen, Ling Wang, The role of survivin in diagnosis, prognosis and treatment of breast cancer by J Thorac Dis 2010; 2: 100-110

You Qiy, The expression of Bcl-2 and survivin protein and its relationship with therapeutic response of neoadjuvant chemotherapy in patients with breast cancer. Published online 2007.

Youssef NS, Hewedi IH, Raboh NM. Immunohistochemical Expression of Survivin in Breast Carcinoma: Relationship with Clinicopathological Parameters, Proliferation and Molecular Classification. Journal of the Egyptian Nat Cancer Instl. 2008;Vol, 20, 4: 348-357

Zhao Y, Wang H, He C. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy. *J Cancer Res Clin Oncol*. 2021;147(12):3653-3664. doi:10.1007/s00432-021-03828-8



REKOMENDASI PERSETUJUAN ETIK

Nomor : 60/UN4.6.4.5.31/ PP36/ 2025

Tanggal: 30 Januari 2025

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH25010053	No Sponsor	
Peneliti Utama	dr. San Winata Badiri, SpB	Sponsor	
Judul Peneliti	Hubungan Ekspresi Survivin dan Her-2 dengan Respon Kemoterapi Neoadjuvan Pada Penderita Kanker Payudara Stadium Lokal Lanjut		
No Versi Protokol	1	Tanggal Versi	17 Januari 2025
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RSUP dr. Wahidin Sudirohusodo Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 30 Januari 2025 sampai 30 Januari 2026	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Prof. dr. Muh Nasrum Massi, PhD, SpMK, Subsp. Bakt(K)	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	dr. Firdaus Hamid, PhD, SpMK(K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan



REKOMENDASI PERSETUJUAN ETIK

Nomor : 60/UN4.6.4.5.31/ PP36/ 2025

Tanggal: 30 Januari 2025

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH25010053	No Sponsor	
Peneliti Utama	dr. San Winata Badiri, SpB	Sponsor	
Judul Peneliti	Hubungan Ekspresi Survivin dan Her-2 dengan Respon Kemoterapi Neoadjuvan Pada Penderita Kanker Payudara Stadium Lokal Lanjut		
No Versi Protokol	1	Tanggal Versi	17 Januari 2025
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RSUP dr. Wahidin Sudirohusodo Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 30 Januari 2025 sampai 30 Januari 2026	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Prof. dr. Muh Nasrum Massi, PhD, SpMK, Subsp. Bakt(K)	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	dr. Firdaus Hamid, PhD, SpMK(K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

DATA PENELITIAN PEMERIKSAAN EKSPRESI SURVIVIN CA MAMMAE

No	Nama	UMUR	RM	TNM	No PA	Survivin	Hasil PA	ER	PR	Her-2	ki67	Respon Kemo
1	Naharia	54	123876	cT4cN2M0	25-79	High	IBC drade 3	(-)	(-)	(+)	N/A	Stable
2	June	50	217920	cT4cN1M0	25-330	High	IBC Grade 3	(+)	(+)	(-)	N/A	Parsial
3	Siti Sulaeha	47	219108	cT3NOM0	25-343	High	ILC Grade 2	(+)	(+)	(+)	N/A	Stable
4	Nurmawati	40	214398	cT4cNOM0	25-398	High	IBC Grade 3	(+)	(+)	(+)	N/A	Stable
5	Andi Nurlang	73	216518	cT4bNOM0	25-385	Moderate	IBC Grade 2	(+)	(+)	(-)	N/A	Parsial
6	Wisdawati	39	217462	cT4aNOM0	25-400	High	IBC Grade 1	(+)	(+)	(-)	N/A	Parsial
7	Kamisa	35	218110	cT4bNOM0	25-404	Moderate	IBC Grade 3	(+)	(+)	(-)	N/A	Parsial
8	Andi Suheni	57	203999	cT4cN2M0	25-565	Moderate	IBC Grade 3	(-)	(-)	(+)	N/A	Stable
9	Sitti Nahda	54	208149	cT4bN1M0	25-799	Moderate	IBC Grade 2	(+)	(+)	(-)	N/A	Parsial
10	Hasna	50	203881	cT4cNOM0	25-717B	Moderate	IBC gr 1 LVSI (-)	(+)	(+)	(-)	N/A	Parsial
11	Fatmawati	52	183095	cT4aNOM0	25-784A	Moderate	IBC Grade 1	(+)	(+)	(-)	N/A	Parsial
12	Taty M	45	214171	cT4bNOM0	25-799	High	IPC	(+)	(+)	(-)	N/A	Parsial
13	Maheria	49	224248	cT4cN2M0	25-846	High	IBC Grade 3	(+)	(+)	(+)	N/A	Stable
14	Andi Punna	55	182881	cT4aNOM0	25-883	High	IBC Grade 1	(+)	(+)	(-)	N/A	Parsial
15	Gustini	44	207374	cT3NOM0	25-861	High	IBC gr 3 LVSI (-)	(-)	(-)	(-)	N/A	Parsial
16	Basse	65	185418	cT4dN2M0	25-949A	High	IBC Grade 3	(-)	(-)	(-)	High	Stable
17	Waode Hatina	47	182963	cT4bN1M0	25-953B	High	IBC Grade 2	(+)	(+)	(+)	N/A	Stable
18	Sia	47	228391	cT4bN1M0	25-987A	High	IBC Grade 3	(-)	(-)	(-)	N/A	Stable
19	Voice Dada	41	225004	cT4bNOM0	25-950B	High	ILC (pleomorfik Pattern) gr 2	(+)	(+)	(-)	N/A	Parsial
20	Hamida	54	225024	cT4dN2M0	25-966	High	IBC Grade 2	(-)	(-)	(+)	N/A	Stable
21	Husna	65	225957	cT4dN2M0	25-978	High	IBC gr 3 LVSI (-)	(+)	(+)	(+)	N/A	Stable
22	Raoda	39	225871	cT4bNOM0	24-989B	High	IBC gr 3 LVSI (-)	(-)	(-)	(+)	N/A	Stable
23	Damaris	67	208593	cT4bNOM0	25-1141	High	IBC grade 2	(-)	(-)	(+)	N/A	Stable
24	Najamia	43	228204	cT4dN2M0	24-1192	High	IBC Grade 3	(+)	(+)	(+)	N/A	Stable
25	Syamsiah Gafur	60	77742	cT4cN1M0	24-1195	High	IBC Grade 3	(-)	(-)	(-)	N/A	Stable
26	Rosa Ranggalean	50	83860	cT4bN000	24-1286	Moderate	IBC Grade 1	(+)	(+)	(-)	N/A	Parsial
27	Jumardiah	60	228969	cT4aNOM0	24-1293	High	IBC grade 2	(+)	(+)	(+)	N/A	Parsial
28	Andi Megawati	42	213955	cT4bNOM0	25-1387A	High	IBC gr 3 LVSI (-)	(+)	(+)	(+)	N/A	Stable
29	Hesti	47	228762	cT4bN2M0	25-1387B	Moderate	IBC grade 3	(+)	(+)	(+)	N/A	Stable
30	Irmayani	44	190937	cT4cNOM0	25-1440	Moderate	IBC grade 3	(+)	(+)	(-)	N/A	Parsial
31	Lindan tirtasuna	43	228372	cT3N1M0	25-1622	Moderate	IBC gr 3 LVSI (-)	(-)	(-)	(+)	High	Stable
32	Yatini	68	231659	cT4bNOM0	25-1652	Moderate	Invasive Lobular gr 3	(+)	(+)	(-)	N/A	Parsial
33	Marwah	54	131720	cT3NOM0	25-1657	Moderate	IBC gr 3 LVSI (-)	(-)	(-)	(+)	High	Parsial
34	Muliati	55	232477	cT4bN1M0	1771	Moderate	IBC gade 3	(+)	(+)	(-)	High	Parsial
35	naisya rahman	68	205680	cT4dNOM0	1776	Moderate	IBC gr 3 LVSI (-)	(-)	(-)	(+)	N/A	stable
36	Mina	49	234630	cT4bN1M0	24-1902	Moderate	Invasive Papillary Ca Mammae	(+)	(+)	(-)	N/A	Parsial
37	Miar	62	212350	cT4bNOM0	24-2081B	Moderate	IBC grade 2	(+)	(+)	(-)	N/A	Parsial
38	Ramla Budy	56	183171	cT4dN2M0	24-2341	Moderate	IBC grade 2	(+)	(+)	(-)	N/A	Parsial
39	Nurhayati	65	233647	cT4cNOM0	25-1928	Moderate	IBC grade 3	(+)	(+)	(-)	N/A	Parsial
40	Andi Farwanti	49	235719	cT3NOM0	24-1943B	High	IBC gr 2	(+)	(+)	(+)	N/A	Stable
41	Hasniawati	47	229938	cT4bNOM0	24-216	Moderate	IBC grade 2	(+)	(+)	(-)	N/A	Parsial
42	Norma	46	231035	cT4aNOM0	24-182 24-1487	Moderate	IBC grade 2	(+)	(+)	(-)	N/A	Parsial
43	Yatini	48	231659	cT4cN1M0	24-207 24-1652	High	IBC grade 3	(+)	(+)	(+)	N/A	Stable
44	Ria Mili	52	383101	cT4bNOM0	25-198	Moderate	IBC grade 2	(+)	(-)	(-)	N/A	Parsial
45	Hadenah	61	231513	cT4cN1M0	25-318	Moderate	IBC grade 2	(+)	(+)	(-)	N/A	Parsial
46	Darmawati	54	1282575	cT4bN1M0	25-258	High	IBC grade 3	(-)	(-)	(+)	N/A	Stable
47	Sakka	55	208143	cT4aNOM0	25-941	High	IBC grade 2	(+)	(+)	(+)	N/A	Stable
48	Aggreini Roosye	48	209896	cT4cN3M0	25-1099	High	IBC grade 3	(-)	(-)	(-)	N/A	Stable
49	Ismiati	48	208810	cT4bN1M0	25-979	High	IBC gr 3	(+)	(+)	(+)	N/A	Stable
50	Sitti Nur	61	192882	cT4cNOM0	25-716	High	IBC grade 3	(-)	(-)	(+)	N/A	Stable
51	Farida	49	212579	cT4cNOM0	23-1272	High	IBC gr 2	(-)	(-)	(+)	N/A	Stable
52	Aminah	47	192251	cT4bN1M0	25-34	Moderate	ILC gr 2	(+)	(+)	(+)	Low	Parsial
53	Nurung	46	184213	cT4aNOM0	25-134	Moderate	IBC gr 2	(+)	(+)	(+)	Low	Parsial

